ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
Disclaimer: On March 1, 2024, The FDA has approved amivantamab-vmjw (RYBREVANT®) plus carboplatin and pemetrexed for the frontline treatment of patients with locally advanced or mNSCLC harboring EGFR exon 20 insertion mutations, as detected by an FDA-approved test.
Login to view comments.
Click here to Login
